Literature DB >> 11843950

Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia.

Gerald M Reaven1.   

Abstract

Recent evidence from the United Kingdom Prospective Diabetes Study convincingly demonstrates that good glycaemic control is difficult to achieve and, despite its positive impact on microvascular complications, is not sufficient to reduce the risk of coronary heart disease (CHD). Syndrome X--a cluster of abnormalities associated with resistance to insulin-mediated glucose uptake that have been implicated in accelerating atherogenesis--provides a useful clinical concept to prevent CHD in patients with type 2 diabetes. Components of syndrome X can include hypertension, hyperinsulinaemia, dyslipidaemia, and a procoagulant state, changes that contribute to the development of atherosclerosis. Low-density lipoprotein cholesterol (LDL-C) levels are usually close to normal, but the LDL-C is present in abnormally small and dense particles. Triglyceride levels are elevated and are associated with an increase in postprandial accumulation of atherogenic, remnant lipoprotein particles. High-density lipoprotein cholesterol levels are typically low. This particular dyslipidaemia, along with hyperinsulinaemia, induces expression of plasminogen activator inhibitor-1, contributing to a prothrombotic state. In addition, plaque formation may be accelerated in insulin-resistant subjects by increased expression of adhesion molecules on endothelial cells and increased rate of monocyte adhesion to cultured endothelial cells. Syndrome X and type 2 diabetes are associated with multiple abnormalities that enhance the atherosclerotic process. The opportunities for new therapeutic approaches to reduce cardiovascular risk will undoubtedly evolve along with our understanding of the complex factors responsible for insulin resistance, compensatory hyperinsulinaemia, and CHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11843950     DOI: 10.1046/j.1462-8902.2001.00037.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  20 in total

Review 1.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Alternative macrophage activation and metabolism.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

3.  Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice.

Authors:  Jibiao Li; Lipeng Bi; Michelle Hulke; Tiangang Li
Journal:  J Biol Chem       Date:  2014-07-01       Impact factor: 5.157

4.  Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.

Authors:  Maurizio Bevilacqua; Barbara Guazzini; Velella Righini; Massimo Barrella; Rosanna Toscano; Enrica Chebat
Journal:  Curr Ther Res Clin Exp       Date:  2004-07

5.  Anthropometric measures and lipid coronary heart disease risk factors in Korean immigrants with type 2 diabetes.

Authors:  Sarah Choi
Journal:  J Cardiovasc Nurs       Date:  2011 Sep-Oct       Impact factor: 2.083

6.  Saturated fatty acids activate ERK signaling to downregulate hepatic sortilin 1 in obese and diabetic mice.

Authors:  Lipeng Bi; John Y L Chiang; Wen-Xing Ding; Winston Dunn; Benjamin Roberts; Tiangang Li
Journal:  J Lipid Res       Date:  2013-07-31       Impact factor: 5.922

7.  The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.

Authors:  K Al Majali; M B Cooper; B Staels; G Luc; M-R Taskinen; D J Betteridge
Journal:  Diabetologia       Date:  2006-01-21       Impact factor: 10.122

8.  Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.

Authors:  Seongah Han; Chien-Ping Liang; Marit Westerterp; Takafumi Senokuchi; Carrie L Welch; Qizhi Wang; Michihiro Matsumoto; Domenico Accili; Alan R Tall
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

9.  Perceptions of coronary heart disease risk in Korean immigrants with type 2 diabetes.

Authors:  Sarah Choi; Sally Rankin; Anita Stewart; Roberta Oka
Journal:  Diabetes Educ       Date:  2008 May-Jun       Impact factor: 2.140

10.  Increased CD36 protein as a response to defective insulin signaling in macrophages.

Authors:  Chien-Ping Liang; Seongah Han; Haruka Okamoto; Ronald Carnemolla; Ira Tabas; Domenico Accili; Alan R Tall
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.